503071-70-3

Basic information

• Product Name: 4-Pyrimidinepropanoic acid, a-(4-fluorophenyl)-b-hydroxy-2-(methylthio)-, methyl ester
• CAS NO: 503071-70-3
• Molecular Formula: C15H15FN2O3S
• Molecular Weight: 322.36
• Mol File: 503071-70-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-Pyrimidinepropanoic acid, a-(4-fluorophenyl)-b-hydroxy-2-(methylthio)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyrimidinepropanoic acid, a-(4-fluorophenyl)-b-hydroxy-2-(methylthio)-, methyl ester(503071-70-3)
• EPA Substance Registry System: 4-Pyrimidinepropanoic acid, a-(4-fluorophenyl)-b-hydroxy-2-(methylthio)-, methyl ester(503071-70-3)

Safety Data

• Hazardous Substances Data: 503071-70-3(Hazardous Substances Data)

Upstream product

• 34837-84-8 4-fluorobenzeneacetic acid methyl ester 
• 1074-68-6 4-formyl-2-(methylthio)pyrimidine 

Downstream Products

• 761000-10-6 3-(4-fluoro-phenyl)-2-(2-methanesulfinyl-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine 
• 761000-08-2 3-(4-fluoro-phenyl)-2-(2-methylsulfanyl-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine 
• 761000-11-7 7-(4-fluoro-phenyl)-6-(2-methanesulfinyl-pyrimidin-4-yl)-2,3-dihydro-pyrazolo[5,1-b]oxazole 
• 761000-09-3 7-(4-fluoro-phenyl)-6-(2-methylsulfanyl-pyrimidin-4-yl)-2,3-dihydro-pyrazolo[5,1-b]oxazole 
• 607721-43-7 4-(4-fluorophenyl)-5-(2-methylsulfanylpyrimidin-4-yl)-1,2-dihydro-pyrazol-3-one 

Relevant articles and documents

Convergent synthesis of 2,3-bisarylpyrazolones through cyclization of bisacylated pyrazolidines and hydrazines

Cyclization of various bisacylated hydrazines and pyrazolidines using DBU or sodium hydride leads to the formation of various mono-, bi- and tricyclic pyrazolone scaffolds in 41-98% yield. The convergent nature by which the precyclization intermediates are constructed allows for rapid derivatization about the pyrazolone core.

The development of monocyclic pyrazolone based cytokine synthesis inhibitors

4-Aryl-5-pyrimidyl based cytokine synthesis inhibitors that contain a novel monocyclic, pyrazolone heterocyclic core are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-α production. One of the compounds (6e) was found to be efficacious in the rat iodoacetate (RIA) in vivo model of osteoarthritis. The X-ray crystal structure of a pyrazolone inhibitor cocrystallized with mutated p38 (mp38) is presented.

Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity

Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis,